Edgewise Therapeutics Q2 2022 Earnings Report
Key Takeaways
Edgewise Therapeutics reported positive results from their EDG-5506 clinical trials in individuals with Becker muscular dystrophy, initiated Phase 2 trials in BMD, and anticipates starting Phase 2 trials in DMD in 2022. The company's cash, cash equivalents, and marketable securities totaled $248.4 million as of June 30, 2022.
Announced positive 2-month interim results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy (BMD).
Initiated Phase 2 trial in BMD and expect to start Phase 2 trial in Duchenne muscular dystrophy (DMD) in 2022.
Cash, cash equivalents and marketable securities were $248.4 million as of June 30, 2022.
Net loss per share was $0.32.
Edgewise Therapeutics
Edgewise Therapeutics
Forward Guidance
Edgewise anticipates that its cash resources on hand will be sufficient to support its planned growth and operations through the end of 2024.